Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS NASDAQ:CLYM NASDAQ:GYRE NYSE:PLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$5.56$4.65$1.43▼$5.69$776.53M0.761.98 million shs1.94 million shsCLYMClimb Bio$12.90$11.22$1.21▼$13.69$738.69M0.071.56 million shs1.18 million shsGYREGyre Therapeutics$7.34$6.54$5.44▼$9.42$818.33M1.89116,825 shs101,740 shsPLXProtalix BioTherapeutics$2.32$2.09$1.36▼$3.19$186.93MN/A1.01 million shs470,793 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics0.00%+11.20%+18.05%+32.38%+283.45%CLYMClimb Bio0.00%-1.38%+18.24%+96.65%+923.81%GYREGyre Therapeutics0.00%+15.94%+18.58%+3.09%-5.90%PLXProtalix BioTherapeutics0.00%+0.87%+15.42%+7.91%+54.67%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$5.56$4.65$1.43▼$5.69$776.53M0.761.98 million shs1.94 million shsCLYMClimb Bio$12.90$11.22$1.21▼$13.69$738.69M0.071.56 million shs1.18 million shsGYREGyre Therapeutics$7.34$6.54$5.44▼$9.42$818.33M1.89116,825 shs101,740 shsPLXProtalix BioTherapeutics$2.32$2.09$1.36▼$3.19$186.93MN/A1.01 million shs470,793 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics0.00%+11.20%+18.05%+32.38%+283.45%CLYMClimb Bio0.00%-1.38%+18.24%+96.65%+923.81%GYREGyre Therapeutics0.00%+15.94%+18.58%+3.09%-5.90%PLXProtalix BioTherapeutics0.00%+0.87%+15.42%+7.91%+54.67%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.13Buy$11.50106.83% UpsideCLYMClimb Bio 3.07Buy$21.7368.43% UpsideGYREGyre Therapeutics 2.00Hold$17.00131.61% UpsidePLXProtalix BioTherapeutics 3.00Buy$12.00417.24% UpsideCurrent Analyst Ratings BreakdownLatest PLX, CLYM, ACRS, and GYRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026ACRSAclaris Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/24/2026CLYMClimb Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.006/12/2026CLYMClimb Bio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$17.006/11/2026CLYMClimb Bio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$19.00 ➝ $20.006/8/2026CLYMClimb Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$35.006/8/2026CLYMClimb Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$35.006/8/2026CLYMClimb Bio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$19.006/2/2026ACRSAclaris Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$13.006/1/2026ACRSAclaris Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/12/2026CLYMClimb Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.005/11/2026GYREGyre Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$8.37M92.81N/AN/A$0.85 per share6.54CLYMClimb BioN/AN/AN/AN/A$3.36 per shareN/AGYREGyre Therapeutics$117.05M6.99$0.22 per share33.03$1.48 per share4.96PLXProtalix BioTherapeutics$76.38M2.45$0.13 per share17.80$0.47 per share4.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$64.92M-$0.56N/AN/AN/A-832.58%-55.89%-38.49%8/6/2026 (Estimated)CLYMClimb Bio-$59.85M-$0.78N/AN/AN/AN/A-31.45%-30.39%8/11/2026 (Estimated)GYREGyre Therapeutics$5.03M-$0.09N/AN/AN/A-5.44%3.13%2.67%8/10/2026 (Estimated)PLXProtalix BioTherapeutics$8.31M$0.18N/A7.48N/A-21.03%-30.89%-11.74%N/ALatest PLX, CLYM, ACRS, and GYRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ACRSAclaris Therapeutics-$0.16-$0.15+$0.01-$0.15$1.32 million$2.00 million5/7/2026Q1 2026CLYMClimb Bio-$0.26-$0.20+$0.06-$0.20N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/ACLYMClimb BioN/AN/AN/AN/AN/AGYREGyre TherapeuticsN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A4.034.03CLYMClimb BioN/A27.8627.86GYREGyre TherapeuticsN/A4.644.06PLXProtalix BioTherapeuticsN/A1.981.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%CLYMClimb Bio69.76%GYREGyre Therapeutics23.99%PLXProtalix BioTherapeutics16.53%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics4.80%CLYMClimb Bio2.60%GYREGyre Therapeutics9.50%PLXProtalix BioTherapeutics6.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100139.66 million132.96 millionOptionableCLYMClimb Bio957.26 million55.77 millionN/AGYREGyre Therapeutics40111.49 million100.90 millionNo DataPLXProtalix BioTherapeutics20080.57 million69.00 millionOptionablePLX, CLYM, ACRS, and GYRE HeadlinesRecent News About These CompaniesContrasting Ablynx (OTCMKTS:ABLYF) and Protalix BioTherapeutics (NYSE:PLX)June 25, 2026 | americanbankingnews.comProtalix BioTherapeutics, Inc. Q1 2026 Earnings Call SummaryMay 15, 2026 | finance.yahoo.comPLX: Chiesi Milestone ReceivedMay 14, 2026 | finance.yahoo.comProtalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2026 Earnings Call TranscriptMay 14, 2026 | insidermonkey.comTranscript: Protalix BioTherapeutics Q1 2026 Earnings Conference CallMay 14, 2026 | uk.finance.yahoo.comProtalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlights: Strong Financial Position ...May 14, 2026 | finance.yahoo.comProtalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comProtalix BioTherapeutics Reports First Quarter 2026 Financial and Business ResultsMay 13, 2026 | prnewswire.comProtalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026May 6, 2026 | prnewswire.comProtalix: Elfabrio Struggles Against Oral CompetitionApril 15, 2026 | seekingalpha.comProtalix Revenue Miss Overshadowed By Milestone-Backed 2026 GuidanceMarch 24, 2026 | seekingalpha.comProtalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business ResultsMarch 18, 2026 | finanznachrichten.deProtalix targets $78M–$83M 2026 revenue with EU milestone, advancing PRX-115March 18, 2026 | seekingalpha.comProtalix BioTherapeutics advances Fabry disease and gout programs during 2025March 18, 2026 | proactiveinvestors.comProtalix: Q4 Earnings SnapshotMarch 18, 2026 | finance.yahoo.comProtalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business ResultsMarch 18, 2026 | finance.yahoo.comProtalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimenMarch 9, 2026 | proactiveinvestors.comChiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase ...March 9, 2026 | tmcnet.comChiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)March 9, 2026 | globenewswire.comProtalix BioTherapeutics (PLX) price target decreased by 12.00% to 11.22February 4, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 2026These 5 Companies Just Made a Massive Bet on ThemselvesBy Thomas Hughes | June 15, 20263 Penny Stocks Under $5 Backed by Real Revenue GrowthBy Chris Markoch | June 20, 2026PLX, CLYM, ACRS, and GYRE Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$5.56 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$5.58 +0.02 (+0.36%) As of 07/2/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Climb Bio NASDAQ:CLYM$12.90 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$12.90 0.00 (0.00%) As of 07/2/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.Gyre Therapeutics NASDAQ:GYRE$7.34 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$7.39 +0.05 (+0.68%) As of 07/2/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Protalix BioTherapeutics NYSE:PLX$2.32 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$2.31 -0.01 (-0.26%) As of 07/2/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Shorting the Grid: Bloom Energy’s $25B AI Power Play Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
